狂犬病疫苗 z-bo 2020-09-18 346

　　The expert demonstration seminar of the national major new drug creation project "Pika adjuvant rabies vaccine" was held in Beijing. Attending the seminar were nearly 30 experts and scholars in the fields of virology, immunology, clinical, biopharmaceuticals, etc., including academicians of the Chinese Academy of Engineering Hou Yunde, Yu Yongxin, Xu Jianguo, Gao Fu, Hong Tao, and Zhuang Hui.

　　Rabies is an acutely fatal infectious disease among the top three reported deaths in my country, and about 80% of patients bitten by clinical rabies exposure III. According to WHO regulations, passive immunization preparations must be used in combination during vaccination. However, the current clinical supply of passive immunization preparations in China is severely insufficient. Therefore, it is necessary to improve the quality of vaccines and preventive effects after exposure.

　　According to Mr. Zhang Yi, the leader of the project team and the chairman of Esheng Group, the pickup adjuvant vaccine is a new, stable, safe and efficient therapeutic rabies vaccine, which is the first in the world. The existing rabies vaccine has only 10%-30% protection against the virus, while the pickup adjuvant rabies vaccine can reach 80%. After being put into clinical use, it can reduce the number of deaths from rabies by more than 50%. At the same time, the vaccine has also successfully shortened the course of immunization from the current 28 days to one week, and the number of injections has been reduced from 5 to 3, which brings great convenience to the vaccinated population.

　　The research and development of the pickup adjuvant vaccine technology lasted 6 years, with an investment of more than 300 million yuan. At present, it has applied for 3 patents in 34 countries around the world, obtained 51 approval certificates, and has independent intellectual property rights. This technology breaks through the limitations of traditional vaccines that only have prevention, and creates a new era of simultaneous treatment and prevention.

　　The experts at the meeting spoke highly of the therapeutic effects of the pickup adjuvant rabies vaccine and put forward constructive opinions on the clinical trial program. They believe that the vaccine will definitely overturn the current pattern of the rabies vaccine market, benefit mankind, and become a new milestone in the history of rabies prevention and treatment in the world.

　　Other therapeutic vaccines developed using pickup adjuvant vaccine technology, such as hepatitis B vaccine, influenza vaccine, and tuberculosis vaccine, will also be launched one after another. Its unique effect has been confirmed by research conducted by Sun Yat-sen University School of Basic Medicine, Singapore National Institute of Defense Technology, National Institutes of Health, and American Tuberculosis Institute.

　　The Pickup Adjuvant Rabies Vaccine Project is the crystallization of the cooperation of global R&D institutions. It has been researched by the National Institutes of Health, the Pasteur Institute in France, the Queensland Institute of Medicine in Australia, the Wuhan Institute of Biological Products, and the Military Veterinary Medicine of the Chinese Academy of Military Medical Sciences. Institute, China Institute for Food and Drug Control, Beijing Drug Safety Evaluation Center, American Aeras Biopharmaceutical Company, Singapore National Defense Technology Research Institute, Department of Immunology, Sun Yat-sen University School of Basic Medicine, Zhaoyan (Suzhou) New Drug Research Center Co., Ltd. Strong support from other cooperative units.